Having your cake and eating it: Office of fair trading proposal for funding new drugs to benefit patients and innovative companies

PharmacoEconomics

Volumn 26, Issue 2, 2008, Pages 91-98

  Godman, Brian ^a   Haycox, Alan ^b   Schwabe, Ulrich ^c   Joppi, Roberta ^a,d   Garattini, Silvio ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Pharmaceutical Drug Department   (Italy)

Author keywords

Formularies; Health policy; Health services accessibility; Pricing; Reimbursement

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ATORVASTATIN; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESOMEPRAZOLE; GENERIC DRUG; HEXACYCLINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MESALAZINE; MOMETASONE FUROATE; NEW DRUG; OMEPRAZOLE; OPIATE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ROSUVASTATIN; SEROTONIN 1D AGONIST; SIMVASTATIN; SUMATRIPTAN SUCCINATE;

DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUSTRY; FINANCIAL MANAGEMENT; HEALTH PROGRAM; HUMAN; NOTE; PRESCRIPTION; PRIORITY JOURNAL; PROSPECTIVE PRICING; UNITED KINGDOM;

EID: 38349070425     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200826020-00001     Document Type: Note

References (58)

1. Audit Commission. Managing the financial implications of NICE guidance. London: Audit Commission Publications, 2005 Sep 8 [online]. Available from URL: http://www.audit-commission.gov.uk/reports/NATIONAL-REPORT.asp?Categ oryID=&ProdID=CC53DDFE-42C8-49c7-BB53-9F6485262 718 [Accessed 2007 Jan 29]
2. Walley T, Mrazek M, Mossialos E. Regulating pharmaceutical markets: improving efficiency and controlling costs in the UK. Int J Health Plann Manage 2005; 20: 375-98
3. National Institute for Health and Clinical Excellence [editorial]. MeReC Bull 2006; 16 (2): 5-7
4. National Institute for Health and Clinical Excellence. How to put NICE guidance into practice: a guide to implementation by organisations. London: NICE, 2005 [online]. Available from URL: http://www.nice.org.uk/usingguidance/ implementationtools/howtoguide/how_to_put_nice_guidance_into_practice.jsp [Accessed 2007 Jan 29]
5. Wells J, Cheong-Leen C. NICE appraisals should be everyone's business. BMJ 2007; 334: 936-8
6. Rawlins M, Culyer A. National Institute for Clinical Excellence and its value judgements. BMJ 2004; 329: 224-7
7. Office of Fair Trading (UK). The pharmaceutical price regulation system: an OFT market study. London: OFT, 2007 Feb [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885.pdf [Accessed 2007 Mar 6]
8. Barrett A, Roques T, Small M, et al. How much will Herceptin really cost? BMJ 2006; 333: 1118-20
9. Rawlins M, Dillion A. What's the evidence that NICE guidance has been implemented? More recent data on NICE implementation show different picture [letter]. BMJ 2005; 330: 1086
10. Wathen B, Dean T. An evaluation of the impact of NICE guidance on GP prescribing. Br J Gen Pract 2004; 54: 103-7
11. Collier J. The pharmaceutical price regulation scheme. BMJ 2007; 334: 435-6
12. Iheanacho I. Slowly, the monster dies. BMJ 2007; 335: 452
13. Burnand A. Drug pricing: misconceptions about PPRS [letter]. BMJ 2007; 335: 578
14. Electronic drug tariff. Newcastle upon Tyne: NHS Business Services Authority, Prescription Pricing Division, 2007 [online]. Available from URL: http://www.ppa.org.uk/edt/November_2007/mindex.htm [Accessed 2007 Nov 12]
15. Simoens S, De Coster S. Sustaining generic medicines: markets in Europe. Leuven: Katholieke Universiteit Leuven, Research Centre for Pharmaceutical Care and Pharmaco-economics, 2006 Apr [online]. Available from URL: http://www.egagenerics.com/doc/simoens-report_2006-04.pdf [Accessed 2006 Oct 16]
16. Paris V. Pharmaceutical regulation in France 1980-2003. Int J Health Plann Manage 2005; 20: 307-28
17. Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 2006; 12 (3): 15-7
18. Andersson K, Sonesson C, Petzold M, et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf 2005; 14 (5): 341-8
19. Andersson K, Jorgensen T, Carlsten A. Physicians' opinions and experiences of the pharmaceutical benefits reform. Scand J Public Health 2006; 34: 654-9
20. Engstr̈om A, Jacob J, Lundin D. Sharp drop in prices after the introduction of generic substitution. Solna: Pharmaceutical Benefits Board (LFN), 2006 [online]. Available from URL: http://www.lfn.se/upload/ pressmeddelanden/generiskt_utbyte_engelsk_061010.pdf [Accessed 2007 Mar 5]
21. Office of Fair Trading (UK). Annexe A: markets for prescription pharmaceuticals in the NHS. In: The pharmaceutical price regulation system: an OFT market study. London: The Office of Fair Trading, 2007 [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/comp_policy/oft885a.pdf [Accessed 2007 Mar 6]
22. Busse R, Schreÿogg J, Henke KD. Regulation of pharmaceutical markets in Germany: improving efficiency and controlling expenditures? Int J Health Plann Manage 2005; 20: 329-49
23. Gelbe Liste Pharmindex [online]. Available from URL: http://www.gelbe- liste.de [Accessed 2007 Apr 18]
24. Prescriptions dispensed in the community statistics for 1995 to 2006: England. London: National Statistics, The Information Centre, 2007 [online]. Available from URL: http://www.ic.nhs.uk/webfiles/publications/ PrescDispensed%2096to06/Bulletin%20220807%20version%20for%202006.pdf [Accessed 2007 Nov 12]
25. Atella V, Schafheutle E, Noyce P, et al. Affordability of medicines and patients' cost-reducing behaviour: empirical evidence based on SUR estimates from Italy and UK. Appl Health Econ Health Policy 2005; 4 (1): 23-35
26. Chaplin S, Duerdin M. When brands are best: brand vs generic prescribing: prescriber guide. Hoboken (NJ): Wiley Interface Ltd, 2006
27. Office of Fair Trading (UK). Annexe M: current price inefficiencies and potential benefits of value-based pricing. In: The pharmaceutical price regulation system: an OFT market study. London: The Office of Fair Trading, 2007 [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/ comp_policy/oft885m.pdf [Accessed 2007 Mar 6]
28. Usher-Smith JA, Ramsbottom T, Pearmain H, et al. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candersartan in a primary care setting. Int J Clin Pract 2007; 61 (1): 15-23
29. APC/DTC briefing: esomeprazole (nexium) - update. London: London New Drugs Group, 2003 Feb. National Electronic Library for Medicines [online]. Available from URL: http://www.druginfozone.nhs.uk/Record%20Viewing/viewRecord. aspx?id=514795 [Accessed 2007 Mar 6]
30. Schreÿogg J, Henke K-D, Busse R. Managing pharmaceutical regulation in Germany [discussion paper 2004/6]. Berlin: Technische Universiẗat Berlin, Fakulẗat Wirtschaft und Management, 2004
31. Rocchi F, Addis A, Martini N, et al. Current national initiatives about drug policies and cost control in Europe: the Italy example. J Ambulatory Care Manage 2004; 27 (2): 127-31
32. Mapelli V, Lucioni C. Spending on pharmaceuticals in Italy: macro constraints with local autonomy. Value Health 2003; 6 Suppl. 1: S31-45
33. Wessling A, Lundin D. The review of drugs against disease caused by acid stomach: a summary. Solna: Pharmaceuticals Benefits Board (LFN), 2006 [online]. Available from URL: http://www.lfn.se/upload/genomgangen/engelsk_sam- manfattning_magsyra_slutgiltig.pdf [Accessed 2007 Mar 5]
34. Hedberg N, Ramsberg J. The review of medicines used for treating migraine: a summary. Solna: Pharmaceuticals Benefits Board (IFN), 2006 [online] Available from URL: http://www.lfn.se/upload/Bakgrundsmaterial/ migraine_review_summary.pdf [Accessed 2007 Mar 5]
35. Hugosson K, Engstr̈om A. Review of medicines against asthma, COPD, and coughs: summary. Solna: Pharmaceuticals Benefits Board (LFN), 2007 [online]. Available from URL: http://www.lfn.se/upload/genomgangen/ gls_asthma_summary_070829.pdf [Accessed 2007 Nov 12]
36. Working guidelines for the pharmaceutical reimbursement review. Solna: Pharmaceuticals Benefits Board (IFN), 2006. Document no.: 1023/2003 [online]. Available from URL: http://www.lfn.se/upload/Genomgangen/ GLS_060815_guidelines_english.pdf [Accessed 2007 Mar 12]
37. Office of Fair Trading (UK). Annexe K: international survey of pharmaceutical pricing and reimbursement schemes. In: The pharmaceutical price regulation system: an OFT market study. London: The Office of Fair Trading, 2007 [online]. Available from URL: http://www.oft.gov.uk/shared_oft/reports/ comp_policy/oft885k.pdf [Accessed 2007 Mar 6]
38. Italy on track to meet drug spending targets this year. SCRIP 2006 May 18; 3056: 3
39. Italian Industry seeks win-win with new government. SCRIP 2006 Jun 16; 3167: 8
40. Across-the-board price cuts annoy Italian industry. SCRIP 2006 Oct 5; 3198: 8
41. Ghislandi S, Krulichova I, Garattini L. Pharmaceutical policy in Italy: towards a structural change? Health Policy 2005; 72: 53-63
42. Schwabe U, Paffrath D, editors. Arzneiverordnungs: report 2007. Heidelberg: Springer Medizin Verlag, 2008
43. Klose G, Schwabe U. Lipidsenkende mittel. In: Schwabe U, Paffrath D, editors. Arzneiverordnungs: report 2004. Heidelberg: Springer Medizin Verlag, 2005: 641-58
44. Rabbata S. Arzneimittelausgaben: das spargesetz wirkt. Dtsch Arzteblatt 2007; 104: A308
45. Maynard A, Bloor K, Freemantle N. Challenges for the National Institute for Clinical Excellence. BMJ 2004; 329: 227-9
46. Hoey R. Experts disagree over NICE's approach for assessing drugs. Lancet 2007; 370: 643-4
47. Moon JC, Bogle RG. Switching statins. BMJ 2006; 332: 1344-5
48. Beishon J, McBride T. Scharaschkin S, et al. for the National Audit Office. Prescribing costs in primary care. London: National Audit Office, 2007 May 18 [online]. Available from URL: http://www.nao.org.uk/publications/ nao_reports/06-07/0607454.pdf [Accessed 2007 May 21]
49. Szecseny J. Influence of attitudes and behaviour of GPs on prescribing costs. Qual Saf Health Care 2003; 12: 6-7
50. Prosser H, Almond S, Walley T. Influences on GPs' decision to prescribe new drugs: the importance of who says what. Fam Pract 2003; 20 (1): 61-8
51. Jones IM, Greenfield S, Bradely P. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001; 323: 378-81
52. Watkins C, Harvey I, Carthy P, et al. Attitudes and behaviour of general practitioners and their prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003; 12: 29-34
53. Mason AR, Drummond MF, Hunter JA, et al. Prescribing incentive schemes: a useful approach? Appl Health Econ Health Policy 2005; 4 (2): 111-7
54. Prosser H, Walley T. A qualitative survey of GPs and PCO stakeholders' views on the importance and influence of costs on prescribing. Soc Sci Med 2005; 60: 1335-46
55. National Institute for Health and Clinical Excellence. Bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ TA118Guidance.pdf [Accessed 2007 Apr 16]
56. National Institute for Health and Clinical Excellence. Lung cancer (non-small cell). Erlotinib: result of appeal. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/nicemedia/pdf/ LungCancerErlotinibAppealDecision.pdf [Accessed 2007 Nov 12]
57. Sudlow CLM, Counsell C. Problems with UK government's risk sharing scheme for assessing drugs for multiple sclerosis. BMJ 2003; 326: 388-92
58. National Institute for Health and Clinical Excellence. Adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis. London: NICE, 2007 [online]. Available from URL: http://www.nice.org.uk/guidance/index. jsp?action=byID&o=11867 [Accessed 2007 Nov 12]